logo
New U.S. vaccine panel includes members who have criticized vaccines and spread misinformation

New U.S. vaccine panel includes members who have criticized vaccines and spread misinformation

CTV Newsa day ago

Dr. Robert Malone gestures as he stands in his barn on his horse farm July 22, 2020, in Madison, Va. (AP Photo/Steve Helber, File)
NEW YORK — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week.
They include a scientist who researched mRNA vaccine technology and became a conservative darling for his criticisms of COVID-19 vaccines, a leading critic of pandemic-era lockdowns, and a professor of operations management.
Kennedy's decision to 'retire' the previous 17-member Advisory Committee on Immunization Practices was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations.
On Tuesday, before he announced his picks, Kennedy said: 'We're going to bring great people onto the ACIP panel – not anti-vaxxers – bringing people on who are credentialed scientists.'
The new appointees include Vicky Pebsworth, a regional director for the National Association of Catholic Nurses, who has been listed as a board member and volunteer director for the National Vaccine Information Center, a group that is widely considered to be a leading source of vaccine misinformation.
Another is Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to prominence during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19.
He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots and has suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years.
Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named.
Abram Wagner of the University of Michigan's school of public health, who investigates vaccination programs, said he's not satisfied with the composition of the committee.
'The previous ACIP was made up of technical experts who have spent their lives studying vaccines,' he said. Most people on the current list 'don't have the technical capacity that we would expect out of people who would have to make really complicated decisions involving interpreting complicated scientific data.'
He said having Pebsworth on the board is 'incredibly problematic' since she is involved in an organization that 'distributes a lot of misinformation.'
Kennedy made the announcement in a social media post on Wednesday.
The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how vaccines that have been approved by the Food and Drug Administration should be used. The CDC's final recommendations are widely heeded by doctors and guide vaccination programs.
The other appointees are:
—Dr. James Hibbeln, who formerly headed a National Institutes of Health group focused on nutritional neurosciences and who studies how nutrition affects the brain, including the potential benefits of seafood consumption during pregnancy.
—Retsef Levi, a professor of operations management at the Massachusetts Institute of Technology who studies business issues related to supply chain, logistics, pricing optimization and health and health care management. In a 2023 video pinned to an X profile under his name, Levi called for the end of the COVID-19 vaccination program, claiming the vaccines were ineffective and dangerous despite evidence they saved millions of lives.
—Dr. James Pagano, an emergency medicine physician from Los Angeles.
—Dr. Michael Ross, a Virginia-based obstetrician and gynecologist.
Of the eight named by Kennedy, perhaps the most experienced in vaccine policy is Meissner, an expert in pediatric infectious diseases at Dartmouth-Hitchcock Medical Center, who has previously served as a member of both ACIP and the Food and Drug Administration's vaccine advisory panel.
During his five-year term as an FDA adviser, the committee was repeatedly asked to review and vote on the safety and effectiveness of COVID-19 vaccines that were rapidly developed to fight the pandemic. In September 2021, he joined the majority of panelists who voted against a plan from the Biden administration to offer an extra vaccine dose to all American adults. The panel instead recommended that the extra shot should be limited to seniors and those at higher risk of the disease.
Ultimately, the FDA disregarded the panel's recommendation and OK'd an extra vaccine dose for all adults.
In addition to serving on government panels, Meissner has helped author policy statements and vaccination schedules for the American Academy of Pediatrics.
ACIP members typically serve in staggered four-year terms, although several appointments were delayed during the Biden administration before positions were filled last year. The voting members all have scientific or clinical expertise in immunization, except for one 'consumer representative' who can bring perspective on community and social facets of vaccine programs.
Kennedy, a leading voice in the anti-vaccine movement before becoming the U.S. government's top health official, has accused the committee of being too closely aligned with vaccine manufacturers and of rubber-stamping vaccines. ACIP policies require members to state past collaborations with vaccine companies and to recuse themselves from votes in which they had a conflict of interest, but Kennedy has dismissed those safeguards as weak.
Most of the people who best understand vaccines are those who have researched them, which usually requires some degree of collaboration with the companies that develop and sell them, said Jason Schwartz, a Yale University health policy researcher.
'If you are to exclude any reputable, respected vaccine expert who has ever engaged even in a limited way with the vaccine industry, you're likely to have a very small pool of folks to draw from,' Schwartz said.
The U.S. Senate confirmed Kennedy in February after he promised he would not change the vaccination schedule. But less than a week later, he vowed to investigate childhood vaccines that prevent measles, polio and other dangerous diseases.
Kennedy has ignored some of the recommendations ACIP voted for in April, including the endorsement of a new combination shot that protects against five strains of meningococcal bacteria and the expansion of vaccinations against RSV.
In late May, Kennedy disregarded the committee and announced the government would change the recommendation for children and pregnant women to get COVID-19 shots.
On Monday, Kennedy ousted all 17 members of the ACIP, saying he would appoint a new group before the next scheduled meeting in late June. The agenda for that meeting has not yet been posted, but a recent federal notice said votes are expected on vaccinations against flu, COVID-19, HPV, RSV and meningococcal bacteria.
A HHS spokesman did not respond to a question about whether there would be only eight ACIP members, or whether more will be named later.
Associated Press reporters Matthew Perrone, Amanda Seitz, Devi Shastri and Laura Ungar contributed to this report.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Mike Stobbe, The Associated Press

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SHA warns public of potential exposure to Hepatitis A at Regina McDonald's
SHA warns public of potential exposure to Hepatitis A at Regina McDonald's

CTV News

time2 hours ago

  • CTV News

SHA warns public of potential exposure to Hepatitis A at Regina McDonald's

The Saskatchewan Health Authority logo can be seen in this CTV News file photo. The Saskatchewan Health Authority (SHA) is investigating a case of Hepatitis A involving a food handler at a Regina McDonald's. On Thursday, the SHA alerted the public of the potential risk of exposure of Hepatitis A at the McDonald's at 2002 Aurora Blvd. The SHA is advising anyone who may have been at or ordered food from that location anytime between May 25 to June 5 to monitor for symptoms for up to 50 days after their last exposure and contact HealthLine 811 to be assessed. Symptoms of Hepatitis A may include fever, loss of appetite, dark urine, light coloured stool, fatigue, nausea, and vomiting, diarrhea, and jaundice, according to the SHA. Hepatitis A is a liver infection cause by a virus that is spread from person to person. While the risk of transmission is very low, the SHA said the possibility still exists. The SHA says to be eligible for a Hepatitis A vaccination, it should be no more than 14 days since the most recent meal from the restaurant.

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies
NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies

Globe and Mail

time2 hours ago

  • Globe and Mail

NASH Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 80+ Companies and 80+ Therapies

DelveInsight's, 'Nonalcoholic Steatohepatitis Pipeline Insight, 2025' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the NASH Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NASH Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the NASH Pipeline. Dive into DelveInsight's comprehensive report today! @ NASH Pipeline Outlook Key Takeaways from the NASH Pipeline Report In May 2025, Novo Nordisk A/S announced a study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period. In May 2025, Akero Therapeutics Inc. conducted a phase 2b study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH). DelveInsight's NASH Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for NASH treatment. The leading NASH Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Promising NASH Pipeline Therapies such as Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. Stay ahead with the most recent pipeline outlook for NASH. Get insights into clinical trials, emerging therapies, and leading companies with NASH@ NASH Treatment Drugs NASH Emerging Drugs Profile Lanifibranor: Inventiva Pharma Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH. MSDC-0602K: Cirius Therapeutics MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH. TERN-501 is a THR-β agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β compared to other THR-β agonists in development. Agonism of THR-β increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR-β stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR-β than for THR-α activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH. HTD 1801: HighTide Biopharma The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). The NASH Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NASH with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NASH Treatment. NASH Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NASH Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NASH market Explore groundbreaking therapies and clinical trials in the NASH Pipeline. Access DelveInsight's detailed report now! @ New NASH Drugs NASH Companies Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical NASH Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of NASH Treatment. Learn about new drugs, NASH Pipeline developments, and key companies with DelveInsight's expert analysis @ NASH Market Drivers and Barriers Scope of the NASH Pipeline Report Coverage- Global NASH Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics and others. NASH Pipeline Therapies- Semaglutide, HEC96719, DA-1241, Sitagliptin, Saroglitazar Magnesium 2mg, Vonafexor, PF-06835919, BMS-986036 and others. NASH Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NASH Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on NASH Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ NASH Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Nonalcoholic Steatohepatitis: Overview Pipeline Therapeutics Therapeutic Assessment Nonalcoholic Steatohepatitis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Lanifibranor: Inventiva Pharma Drug profiles in the detailed report….. Mid Stage Products (Phase II) TERN-501: Terns Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) LY3849891: Eli Lilly and Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name : Company name Drug profiles in the detailed report….. Inactive Products Nonalcoholic Steatohepatitis Key Companies Nonalcoholic Steatohepatitis Key Products Nonalcoholic Steatohepatitis- Unmet Needs Nonalcoholic Steatohepatitis- Market Drivers and Barriers Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion Nonalcoholic Steatohepatitis Analyst Views Nonalcoholic Steatohepatitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Health Data Interoperability Market to Hit US$352.13 Billion by 2032 with 22.65% CAGR
Health Data Interoperability Market to Hit US$352.13 Billion by 2032 with 22.65% CAGR

Globe and Mail

time3 hours ago

  • Globe and Mail

Health Data Interoperability Market to Hit US$352.13 Billion by 2032 with 22.65% CAGR

According to a recent report by Coherent Market Insights, the global Health Data Interoperability Market is estimated to be valued at USD 84.58 billion in 2025 and is expected to reach USD 352.13 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 22.65% from 2025 to 2032. The strong growth of the market is driven by the rising demand for seamless data exchange among healthcare providers, the pursuit of enhanced patient care, and the growing adoption of electronic health records (EHRs) and other digital health technologies. Global Health Data Interoperability Market Key Takeaways According to Coherent Market Insights (CMI), the global health data operability care market size is projected to grow more than 4.1X, increasing from USD 84.58 Bn in 2025 to USD 352.13 Bn by 2032, at a CAGR of 22.65%. By deployment model, cloud-based segment is expected to account for nearly two-thirds of the global health data interoperability market share in 2025. Based on component, software category is anticipated to generate a market revenue of about USD 45.92 Bn in 2025. By type, electronic health records (EHRs) segment will likely account for more than two-fifths of the global market revenue share by 2025. North America is expected to retain its monopoly in the global market due to increasing adoption of digital health technologies. As per Coherent Market Insights' latest health data interoperability market research, North America will hold nearly 2/5 of the global market share in 2025. Asia Pacific health data interoperability market is estimated to be valued at around USD 25.62 Bn in 2025. Growing Adoption of Electronic Health Records (EHRs) Boosting Market Growth Coherent Market Insights' new health data interoperability market analysis offers insights into prominent factors driving industry growth. Increasing adoption of electronic health records (EHRs) is one key growth driver. In the contemporary world, more and more hospitals and clinics are embracing electronic health records. For instance, as per the National Center for Health Statistics, about 88.2% of office-based physicians in the United States use an EMR/EHR system. High adoption of EHRs is creating an urgent need for seamless data exchange across various healthcare systems. This will drive demand for health data interoperability solutions during the forecast period. High Implementation Cost and Lack of Standardization Limiting Market Growth The future health data interoperability market outlook looks promising. However, lack of universal standards and high implementation costs are expected to restrain market growth to some extent. Different healthcare providers often use disparate EHR systems, making seamless data exchange challenging. Absence of universally accepted interoperability standards across regions can hinder consistent integration and data sharing, negatively affecting the health data interoperability market growth. Implementing interoperable systems requires substantial investments in both infrastructure and software. This deters smaller clinics and healthcare providers, especially across underserved regions, from opting for these systems, thereby reducing the health data interoperability market demand. Purchase Now Up to 25% Discount on This Premium Research Report: Rapid Shift Towards Value-Based Care to Create Lucrative Growth Avenues Growing adoption of value-based care (VBC) models is driving demand for improved patient outcomes and cost efficiency across healthcare systems. This transition necessitates seamless health data interoperability to enable coordinated care as well as real-time data exchange and performance measurement. As a result, the shift towards VBC is unlocking significant growth opportunities for health data interoperability companies. Policies like HITECH Act and EU GDPR mandate interoperability as well as patient access to data. They will also create lucrative growth prospects for health data interoperability solution providers in the coming years. Policies like the HITECH Act and the EU GDPR emphasize interoperability as well as patient access to health data. These regulations are expected to drive demand for health data interoperability solutions, creating lucrative growth opportunities for industry players. Impact of AI on the Health Data Interoperability Market AI is revolutionizing the health data interoperability industry by tackling long-standing challenges like fragmented data and inconsistent data standards. Organizations use machine learning and NLP to automate data mapping, convert unstructured records into structured formats, and streamline EHR integration. AI-driven predictive analytics can forecast data exchange needs, enhance real‑time clinical workflows, and reduce clinical errors. Federated learning frameworks allow AI models to train across multiple organizations without moving sensitive patient data, which improves privacy and fosters collaboration. AI-powered interoperability solutions are gaining immense traction in the modern healthcare ecosystem. This is due to their potential to boost operational efficiency, enable personalized care, reduce costs, and accelerate the transition towards value‑based models. Emerging Health Data Interoperability Market Trends Rising demand for patient-centric care is a key growth-shaping trend in the market. Today, patients want access to their health information through mobile apps and patient portals. This is creating a need for connected systems. Growing popularity of cloud-based interoperability solutions is expected to boost the overall health data interoperability market value. These scalable and cost-effective platforms are gradually replacing on-premise systems across various regions. Rise of telehealth services and adoption of remote patient monitoring devices are also positively impacting the health data interoperability market growth. These technologies require robust interoperability solutions to ensure seamless data flow between patients, healthcare providers, and monitoring platforms. Analyst's View 'The global health data interoperability market is poised to exhibit robust growth, owing to increasing government mandates and regulatory frameworks, widespread adoption of electronic health and medical record systems (EHR/EMR), and a growing emphasis on value-based care models,' said senior analyst Komal Dighe. Current Events and Their Impact on the Health Data Interoperability Market Event Description and Impact U.S. HTI-1 Final Rule Description: U.S. HTI-1 Final Rule enforces FHIR-based standards for certified health IT systems. Impact: This drives adoption of compliant interoperability platforms and APIs, leading to market growth. EU's European Health Data Space (EHDS) Rollout Description: European Union's EHDS initiative, officially implemented in 2025, requires member states to adopt standardized cross-border health data sharing through unified interoperability frameworks. Impact: This is driving health IT vendors to comply with EHDS standards as well as boosting demand for FHIR-based platforms and multilingual data exchange solutions. Competitor Insights Key companies in health data interoperability market report include: - Cerner Corporation - Epic Systems Corporation - Meditech - Allscripts Healthcare Solutions - athenahealth - InterSystems Corporation - Philips Healthcare - GE Healthcare - Oracle Health Sciences - NextGen Healthcare - IBM Watson Health - Microsoft Health - McKesson Corporation - Siemens Healthineers - Infor Healthcare Key Developments In March 2025, 1upHealth sets a new benchmark for health data interoperability with the launch of its new 1up Platform. The new platform, built on a modern lakehouse architecture, is designed to deliver 'Health Data On Demand'. It offers real-time data access, scalable management, and advanced analytics to help healthcare organizations enhance operational efficiency, care quality, and patient outcomes. In March 2025, Epic Systems Corporation unveiled industry-leading Genomics, AI, and interoperability solutions at the HIMSS 2025 Conference. These new solutions are designed to help healthcare organizations advance in rapidly evolving environment. They have the potential to enhance clinical care, streamline operations, and foster more personalized patient treatments. In January 2025, MEDITECH unveiled its new set of APIs fully compatible with version 4 of the United States Core Data for Interoperability (USCDI v4). This new launch highlights the company's leadership in advancing standards-based interoperability across healthcare systems. Market Segmentation Deployment Model Insights Cloud-Based On-Premises Component Insights Hardware Software Services Type Insights Electronic Health Records (EHR) Health Information Exchange (HIE) Interoperability Solutions Integration Platforms Interoperability Level Insights Foundational Interoperability Structural Interoperability Semantic Interoperability End User Insights Healthcare Providers Healthcare Payers Pharmaceutical Companies Research Institutions Regional Insights North America U.S. Canada Latin America Brazil Argentina Mexico Rest of Latin America Europe Germany U.K. Spain France Italy Russia Rest of Europe Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific Middle East GCC Countries Israel Rest of Middle East Africa South Africa North Africa § Central Africa Get Customization on this Report: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Raj Shah Email: Send Email Phone: +1-252-477-1362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States City: Burlingame State: California Country: United States Website:

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store